{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:38:43Z","timestamp":1794274723024,"version":"4.9.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T00:00:00Z","timestamp":1737158400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["No. 82272985"],"award-info":[{"award-number":["No. 82272985"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["No. 2022A1515012293"],"award-info":[{"award-number":["No. 2022A1515012293"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010256","name":"Guangzhou Municipal Science and Technology Project","doi-asserted-by":"publisher","award":["No. 2024A03J0897"],"award-info":[{"award-number":["No. 2024A03J0897"]}],"id":[{"id":"10.13039\/501100010256","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Ovarian cancer (OC) is a heterogeneous cancer. In contrast to other tumor cells, which rely primarily on aerobic glycolysis (Warburg effect) as their energy source, oxidative phosphorylation (OXPHOS) is also one of its major metabolic modes. Piwi-interacting RNAs (piRNAs) play a regulatory function in various biological processes in tumor cells. However, the role and mechanisms of piRNAs in OC and mitochondrial OXPHOS remain to be elucidated. Here, we found that piR-26441 was aberrantly downregulated in OC, and its overexpression suppressed the malignant features of OC cells and tumor growth in a xenograft model. Moreover, overexpression of piR-26441 significantly reduced mitochondrial OXPHOS levels in OC cells. Furthermore, piR-26441 directly binds to and upregulates the expression of YTHDC1 in OC cells. piR-26441 also increased m6A levels, thereby interacting with YTHDC1 to destabilize the mRNA of TSFM. The resultant TSFM loss reduced mitochondrial complex I activity and mitochondrial OXPHOS, leading to mitochondrial dysfunction in OC cells, increased reactive oxygen species levels, and thus, DNA damage and apoptosis in OC cells, thereby inhibiting OC progression. Additionally, ago-piR-26441 suppressed tumor growth and mitochondrial metabolism in the patient-derived organoid model. Altogether, piR-26441 could inhibit OC cell growth via the YTHDC1\/TSFM signaling axis, underscoring its significant importance in the context of OC, as well as offering potential as a therapeutic target.<\/jats:p>","DOI":"10.1038\/s41419-025-07340-6","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:00:48Z","timestamp":1737187248000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["piR-26441 inhibits mitochondrial oxidative phosphorylation and tumorigenesis in ovarian cancer through m6A modification by interacting with YTHDC1"],"prefix":"10.1038","volume":"16","author":[{"given":"Jing","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bu-Min","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Meng","family":"Ji","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-Juan","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie-Lin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-Chen","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-Chun","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3226-8127","authenticated-orcid":false,"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5122-3656","authenticated-orcid":false,"given":"Shuo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,18]]},"reference":[{"key":"7340_CR1","first-page":"12","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA: Cancer J. Clin. 2024;74:12\u201349.","journal-title":"CA: Cancer J. Clin"},{"key":"7340_CR2","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100149","volume":"6","author":"SI Kim","year":"2021","unstructured":"Kim SI, Kim JW. Role of surgery and hyperthermic intraperitoneal chemotherapy in ovarian cancer. ESMO open. 2021;6:100149.","journal-title":"ESMO open"},{"key":"7340_CR3","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1097\/IGC.0b013e31826bd1f2","volume":"22","author":"F Modugno","year":"2012","unstructured":"Modugno F, Edwards RP. Ovarian cancer: prevention, detection, and treatment of the disease and its recurrence. Molecular mechanisms and personalized medicine meeting report. Int. J. Gynecol. Cancer : J. Int. Gynecol. Cancer Soc. 2012;22:S45\u201357.","journal-title":"Int. J. Gynecol. Cancer : J. Int. Gynecol. Cancer Soc."},{"key":"7340_CR4","doi-asserted-by":"publisher","first-page":"23210","DOI":"10.18632\/aging.203613","volume":"13","author":"Q Tan","year":"2021","unstructured":"Tan Q, Liu H, Xu J, Mo Y, Dai F. Integrated analysis of tumor-associated macrophage infiltration and prognosis in ovarian cancer. Aging. 2021;13:23210\u201332.","journal-title":"Aging"},{"key":"7340_CR5","doi-asserted-by":"publisher","first-page":"3976","DOI":"10.7150\/jca.47695","volume":"12","author":"S Liu","year":"2021","unstructured":"Liu S, Wu M, Wang F. Research Progress in Prognostic Factors and Biomarkers of Ovarian Cancer. J. Cancer. 2021;12:3976\u201396.","journal-title":"J. Cancer"},{"key":"7340_CR6","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1186\/s13071-016-1815-8","volume":"9","author":"P Liu","year":"2016","unstructured":"Liu P, Dong Y, Gu J, Puthiyakunnon S, Wu Y, Chen XG. Developmental piRNA profiles of the invasive vector mosquito Aedes albopictus. Parasites Vectors. 2016;9:524.","journal-title":"Parasites Vectors"},{"key":"7340_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-019-1052-9","volume":"18","author":"Y Liu","year":"2019","unstructured":"Liu Y, Dou M, Song X, Dong Y, Liu S, Liu H, et al. The emerging role of the piRNA\/piwi complex in cancer. Mol. Cancer. 2019;18:123.","journal-title":"Mol. Cancer"},{"key":"7340_CR8","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1111\/cas.13300","volume":"108","author":"J Yin","year":"2017","unstructured":"Yin J, Jiang XY, Qi W, Ji CG, Xie XL, Zhang DX, et al. piR-823 contributes to colorectal tumorigenesis by enhancing the transcriptional activity of HSF1. Cancer Sci. 2017;108:1746\u201356.","journal-title":"Cancer Sci."},{"key":"7340_CR9","doi-asserted-by":"publisher","first-page":"108613","DOI":"10.1016\/j.biopha.2019.108613","volume":"112","author":"T Sun","year":"2019","unstructured":"Sun T, Wu R, Ming L. The role of m6A RNA methylation in cancer. Biomed. Pharmacother. 2019;112:108613.","journal-title":"Biomed. Pharmacother."},{"key":"7340_CR10","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1182\/blood.2019003764","volume":"137","author":"H Han","year":"2021","unstructured":"Han H, Fan G, Song S, Jiang Y, Qian C, Zhang W, et al. piRNA-30473 contributes to tumorigenesis and poor prognosis by regulating m6A RNA methylation in DLBCL. Blood. 2021;137:1603\u201314.","journal-title":"Blood"},{"key":"7340_CR11","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1089\/ars.2016.6750","volume":"26","author":"G Gentric","year":"2017","unstructured":"Gentric G, Mieulet V, Mechta-Grigoriou F. Heterogeneity in Cancer Metabolism: New Concepts in an Old Field. Antioxid. Redox Signaling 2017;26:462\u201385.","journal-title":"Antioxid. Redox Signaling"},{"key":"7340_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.cell.2016.12.039","volume":"168","author":"MG Vander Heiden","year":"2017","unstructured":"Vander Heiden MG, DeBerardinis RJ. Understanding the Intersections between Metabolism and Cancer Biology. Cell. 2017;168:657\u201369.","journal-title":"Cell"},{"key":"7340_CR13","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1126\/science.123.3191.309","volume":"123","author":"O Warburg","year":"1956","unstructured":"Warburg O. On the origin of cancer cells. Science 1956;123:309\u201314.","journal-title":"Science"},{"key":"7340_CR14","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"P Caro","year":"2012","unstructured":"Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22:547\u201360.","journal-title":"Cancer Cell"},{"key":"7340_CR15","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ccr.2012.11.020","volume":"23","author":"F Vazquez","year":"2013","unstructured":"Vazquez F, Lim JH, Chim H, Bhalla K, Girnun G, Pierce K, et al. PGC1\u03b1 expression defines a subset of human melanoma tumors with increased mitochondrial capacity and resistance to oxidative stress. Cancer Cell. 2013;23:287\u2013301.","journal-title":"Cancer Cell"},{"key":"7340_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/nm.4055","volume":"22","author":"R Camarda","year":"2016","unstructured":"Camarda R, Zhou AY, Kohnz RA, Balakrishnan S, Mahieu C, Anderton B, et al. Inhibition of fatty acid oxidation as a therapy for MYC-overexpressing triple-negative breast cancer. Nat. Med. 2016;22:427\u201332.","journal-title":"Nat. Med."},{"key":"7340_CR17","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.cell.2015.12.034","volume":"164","author":"CT Hensley","year":"2016","unstructured":"Hensley CT, Faubert B, Yuan Q, Lev-Cohain N, Jin E, Kim J, et al. Metabolic Heterogeneity in Human Lung Tumors. Cell. 2016;164:681\u201394.","journal-title":"Cell"},{"key":"7340_CR18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.cmet.2018.09.002","volume":"29","author":"G Gentric","year":"2019","unstructured":"Gentric G, Kieffer Y, Mieulet V, Goundiam O, Bonneau C, Nemati F, et al. PML-Regulated Mitochondrial Metabolism Enhances Chemosensitivity in Human Ovarian Cancers. Cell Metab. 2019;29:156\u201373.e10.","journal-title":"Cell Metab."},{"key":"7340_CR19","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.devcel.2011.01.004","volume":"20","author":"H Huang","year":"2011","unstructured":"Huang H, Gao Q, Peng X, Choi SY, Sarma K, Ren H, et al. piRNA-associated germline nuage formation and spermatogenesis require MitoPLD profusogenic mitochondrial-surface lipid signaling. Dev. Cell. 2011;20:376\u201387.","journal-title":"Dev. Cell"},{"key":"7340_CR20","doi-asserted-by":"publisher","first-page":"W385","DOI":"10.1093\/nar\/gkq392","volume":"38","author":"PJ Huang","year":"2010","unstructured":"Huang PJ, Liu YC, Lee CC, Lin WC, Gan RR, Lyu PC, et al. DSAP: deep-sequencing small RNA analysis pipeline. Nucleic Acids Res. 2010;38:W385\u201391.","journal-title":"Nucleic Acids Res."},{"key":"7340_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41420-023-01488-w","volume":"9","author":"Q Li","year":"2023","unstructured":"Li Q, Xie B, Chen X, Lu B, Chen S, Sheng X, et al. SNORD6 promotes cervical cancer progression by accelerating E6-mediated p53 degradation. Cell Death Discov. 2023;9:192.","journal-title":"Cell Death Discov."},{"key":"7340_CR22","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/bs.mie.2015.03.001","volume":"560","author":"D Dominissini","year":"2015","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Amariglio N, Rechavi G. Transcriptome-Wide Mapping of N6-Methyladenosine by m6A-Seq. Methods Enzymol.2015;560:131\u201347.","journal-title":"Methods Enzymol."},{"key":"7340_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-69488-9","volume":"10","author":"Y Nanki","year":"2020","unstructured":"Nanki Y, Chiyoda T, Hirasawa A, Ookubo A, Itoh M, Ueno M, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci. Rep. 2020;10:12581.","journal-title":"Sci. Rep."},{"key":"7340_CR24","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1016\/j.devcel.2023.04.012","volume":"58","author":"W Senkowski","year":"2023","unstructured":"Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC, et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Dev. Cell. 2023;58:1106\u201321.e7.","journal-title":"Dev. Cell"},{"key":"7340_CR25","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1158\/2159-8290.CD-20-0455","volume":"11","author":"S Zhang","year":"2021","unstructured":"Zhang S, Iyer S, Ran H, Dolgalev I, Gu S, Wei W, et al. Genetically Defined, Syngeneic Organoid Platform for Developing Combination Therapies for Ovarian Cancer. Cancer Discov. 2021;11:362\u201383.","journal-title":"Cancer Discov."},{"key":"7340_CR26","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41392-023-01642-x","volume":"8","author":"L Sun","year":"2023","unstructured":"Sun L, Liu H, Ye Y, Lei Y, Islam R, Tan S, et al. Smart nanoparticles for cancer therapy. Signal Transduct. Target. Ther. 2023;8:418.","journal-title":"Signal Transduct. Target. Ther."},{"key":"7340_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1038\/s41573-021-00219-z","volume":"20","author":"M Winkle","year":"2021","unstructured":"Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics - challenges and potential solutions. Nat. Rev. Drug Discov. 2021;20:629\u201351.","journal-title":"Nat. Rev. Drug Discov."},{"key":"7340_CR28","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, Moshitch-Moshkovitz S, Schwartz S, Salmon-Divon M, Ungar L, Osenberg S, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485:201\u20136.","journal-title":"Nature"},{"key":"7340_CR29","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1086\/508434","volume":"79","author":"JA Smeitink","year":"2006","unstructured":"Smeitink JA, Elpeleg O, Antonicka H, Diepstra H, Saada A, Smits P, et al. Distinct clinical phenotypes associated with a mutation in the mitochondrial translation elongation factor EFTs. Am. J. Hum. Genet. 2006;79:869\u201377.","journal-title":"Am. J. Hum. Genet."},{"key":"7340_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-41483-9","volume":"9","author":"E Perli","year":"2019","unstructured":"Perli E, Pisano A, Glasgow RIC, Carbo M, Hardy SA, Falkous G, et al. Novel compound mutations in the mitochondrial translation elongation factor (TSFM) gene cause severe cardiomyopathy with myocardial fibro-adipose replacement. Sci. Rep. 2019;9:5108.","journal-title":"Sci. Rep."},{"key":"7340_CR31","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1113\/jphysiol.2003.049478","volume":"552","author":"JF Turrens","year":"2003","unstructured":"Turrens JF. Mitochondrial formation of reactive oxygen species. J. Physiol. 2003;552:335\u201344.","journal-title":"J. Physiol."},{"key":"7340_CR32","first-page":"9950","volume":"13","author":"C Nantasupha","year":"2021","unstructured":"Nantasupha C, Thonusin C, Charoenkwan K, Chattipakorn S, Chattipakorn N. Metabolic reprogramming in epithelial ovarian cancer. Am. J. Transl. Res. 2021;13:9950\u201373.","journal-title":"Am. J. Transl. Res."},{"key":"7340_CR33","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"7340_CR34","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1007\/s00439-017-1803-x","volume":"136","author":"I Kozlovski","year":"2017","unstructured":"Kozlovski I, Siegfried Z, Amar-Schwartz A, Karni R. The role of RNA alternative splicing in regulating cancer metabolism. Hum. Genet. 2017;136:1113\u201327.","journal-title":"Hum. Genet."},{"key":"7340_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.bcp.2014.08.011","volume":"92","author":"DH Suh","year":"2014","unstructured":"Suh DH, Kim HS, Kim B, Song YS. Metabolic orchestration between cancer cells and tumor microenvironment as a co-evolutionary source of chemoresistance in ovarian cancer: a therapeutic implication. Biochem. Pharmacol. 2014;92:43\u201354.","journal-title":"Biochem. Pharmacol."},{"key":"7340_CR36","doi-asserted-by":"publisher","first-page":"337.","DOI":"10.3390\/cancers10090337","volume":"10","author":"AP Nayak","year":"2018","unstructured":"Nayak AP, Kapur A, Barroilhet L, Patankar MS. Oxidative Phosphorylation: A Target for Novel Therapeutic Strategies Against Ovarian Cancer. Cancers. 2018;10:337.","journal-title":"Cancers"},{"key":"7340_CR37","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/s41588-023-01320-2","volume":"55","author":"NL Burdett","year":"2023","unstructured":"Burdett NL, Willis MO, Alsop K, Hunt AL, Pandey A, Hamilton PT, et al. Multiomic analysis of homologous recombination-deficient end-stage high-grade serous ovarian cancer. Nat. Genet. 2023;55:437\u201350.","journal-title":"Nat. Genet."},{"key":"7340_CR38","doi-asserted-by":"publisher","first-page":"e0190485","DOI":"10.1371\/journal.pone.0190485","volume":"13","author":"G Singh","year":"2018","unstructured":"Singh G, Roy J, Rout P, Mallick B. Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory networks in epithelial ovarian cancers. PloS one. 2018;13:e0190485.","journal-title":"PloS one"},{"key":"7340_CR39","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.7150\/ijbs.81595","volume":"19","author":"X Wang","year":"2023","unstructured":"Wang X, Chen Q, Bing Z, Zhou S, Xu Z, Hou Y, et al. Low expression of m6A reader YTHDC1 promotes progression of ovarian cancer via PIK3R1\/STAT3\/GANAB axis. Int. J. Biol. Sci. 2023;19:4672\u201388.","journal-title":"Int. J. Biol. Sci."},{"key":"7340_CR40","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1038\/s12276-023-00997-z","volume":"55","author":"B Yan","year":"2023","unstructured":"Yan B, Li X, Peng M, Zuo Y, Wang Y, Liu P, et al. The YTHDC1\/GLUT3\/RNF183 axis forms a positive feedback loop that modulates glucose metabolism and bladder cancer progression. Exp. Mol. Med. 2023;55:1145\u201358.","journal-title":"Exp. Mol. Med."},{"key":"7340_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1016\/j.biocel.2013.12.011","volume":"48","author":"V Boczonadi","year":"2014","unstructured":"Boczonadi V, Horvath R. Mitochondria: impaired mitochondrial translation in human disease. Int. J. Biochem. Cell Biol. 2014;48:77\u201384.","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"7340_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.967342","volume":"12","author":"J Xiang","year":"2022","unstructured":"Xiang J, Su R, Wu S, Zhou L. Construction of a prognostic signature for serous ovarian cancer based on lactate metabolism-related genes. Front. Oncol. 2022;12:967342.","journal-title":"Front. Oncol."},{"key":"7340_CR43","doi-asserted-by":"crossref","unstructured":"Ohshima K, Morii E Metabolic Reprogramming of Cancer Cells during Tumor Progression and Metastasis. Metabolites. 2021;11.","DOI":"10.3390\/metabo11010028"},{"key":"7340_CR44","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/jcbfm.2012.211","volume":"33","author":"IN Singh","year":"2013","unstructured":"Singh IN, Gilmer LK, Miller DM, Cebak JE, Wang JA, Hall ED. Phenelzine mitochondrial functional preservation and neuroprotection after traumatic brain injury related to scavenging of the lipid peroxidation-derived aldehyde 4-hydroxy-2-nonenal. J. Cereb. Blood Flow. Metab. : Off. J. Int. Soc. Cereb. Blood Flow. Metab. 2013;33:593\u20139.","journal-title":"J. Cereb. Blood Flow. Metab. : Off. J. Int. Soc. Cereb. Blood Flow. Metab."},{"key":"7340_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106114","volume":"177","author":"J Feng","year":"2022","unstructured":"Feng J, Wang X, Ye X, Ares I, Lopez-Torres B, Mart\u00ednez M, et al. Mitochondria as an important target of metformin: The mechanism of action, toxic and side effects, and new therapeutic applications. Pharmacol. Res. 2022;177:106114.","journal-title":"Pharmacol. Res."}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07340-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07340-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T08:53:06Z","timestamp":1737190386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-025-07340-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,18]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["7340"],"URL":"https:\/\/doi.org\/10.1038\/s41419-025-07340-6","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,18]]},"assertion":[{"value":"3 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The Ethics Committee of the Third Affiliated Hospital of Guangzhou Medical University (No: 2021-055) approved the use of human tissue in this study. All animal experiments were approved and conducted by Guangdong Medical Laboratory Animal Center (Approval No. B202208-8). We conformed with the Helsinki Declaration of 1975 (as revised in 2008) concerning Human and Animal Rights.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}],"article-number":"25"}}